Lori Anne Kunkel Sells $345K of Enliven Therapeutics Inc (ELVN) — SEC Form 4, Jun 09, 2026

Open-Market Net Sale · SEC Form 4
−$345,351
10b5-1 Plan

Equity position changed by -16.2%

Reporting Owner
Lori Anne Kunkel
Director
TXN 2026-06-05 · FILED 2026-06-09
Equity Position 51.9K sh 61,884 → 51,884
Equity Change -16.2% shares held after vs before
Filing Lag 2 business days within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership

Enliven Therapeutics Inc

ELVN CIK 0001672619
All Enliven Therapeutics Inc insider activity
Filing Date
2026-06-09
Report Date
2026-06-09
Accession No.
0001536368-26-000004
Accepted At
2026-06-09 20:49 UTC
Reporting Owner
Name Relationship
Lori Anne Kunkel CIK 0001536368
Director
Lori Anne Kunkel at Enliven Therapeutics Inc Full insider history
Bought (12 mo) —
Sold (12 mo) $850,254
More from this insider at Enliven Therapeutics Inc
2026-11-03 Exercise — View
2026-07-08 Sell -$504,903 View
2026-02-18 Award — View
2025-12-19 Exercise — View
2025-02-10 Award — View
All filings by this insider at Enliven Therapeutics Inc
Non-Derivative Securities Transactions
Title Date Type Shares Price Net Total Post-Txn Ownership
Common StockF1F2F3 2026-06-05 S - Sale 10b5-1 7,779 D $34.28 -$266,659 54,105 Direct
Common StockF1F4 2026-06-05 S - Sale 10b5-1 1,867 D $35.36 -$66,012 52,238 Direct
Common StockF1F5 2026-06-05 S - Sale 10b5-1 354 D $35.82 -$12,680 51,884 Direct
Non-Derivative Holdings
Title Shares Held Ownership
Common StockF3F6 0 Indirect See footnote
Footnotes (6)
F1
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 Show more
F2
This transaction was executed in multiple trades at prices ranging from $33.7383 to $34.7358. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Show more
F3
The number of shares held reflects the transfer of 31,172 shares of Common Stock from Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE to the Reporting Person . Show more
F4
This transaction was executed in multiple trades at prices ranging from $34.759 to $35.7574. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Show more
F5
This transaction was executed in multiple trades at prices ranging from $35.7595 to $35.9456. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Show more
F6
The shares were held by Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE. Show more

Related filings at Enliven Therapeutics Inc

Institutional Holders
13F holders · Jun 30, 2026 212 institutional managers reporting a position
Largest by reported value
  1. Fmr Llc $509M
  2. Orbimed Advisors Llc $344M
  3. Polar Capital Holdings Plc $326M
5%+ Holders · 13D/G 6 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Enliven Therapeutics Inc
All Enliven Therapeutics Inc insider activity
GET /v1/forms/4/0001536368-26-000004 API docs
View Original SEC Filing